LPL Financial
CYTK icon

LPL Financial’s Cytokinetics CYTK Stock Holding History

LPL Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Buy
16,666
+4,294
+35% +$308K ﹤0.01% 4106
2026
Q1 		$815K Buy
12,372
+176
+1% +$11.2K ﹤0.01% 4354
2025
Q4 		$775K Buy
12,196
+995
+9% +$61.9K ﹤0.01% 4326
2025
Q3 		$616K Sell
11,201
-8,577
-43% -$353K ﹤0.01% 4453
2025
Q2 		$653K Buy
19,778
+4,917
+33% +$171K ﹤0.01% 4143
2025
Q1 		$597K Buy
14,861
+873
+6% +$40.1K ﹤0.01% 4001
2024
Q4 		$658K Buy
13,988
+870
+7% +$45.2K ﹤0.01% 3851
2024
Q3 		$693K Buy
13,118
+239
+2% +$13.3K ﹤0.01% 3728
2024
Q2 		$698K Sell
12,879
-1,068
-8% -$64.5K ﹤0.01% 3573
2024
Q1 		$978K Buy
13,947
+77
+0.6% +$5.96K ﹤0.01% 3201
2023
Q4 		$1.16M Buy
+13,870
New +$502K ﹤0.01% 2919

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LPL Financial's CYTK Position: Q2 2026 in Review

LPL Financial increased its Cytokinetics (CYTK) stake by 35% in Q2 2026, buying an estimated $308K and bringing the position to 16,666 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #4106.

LPL Financial first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • LPL Financial held 16,666 shares of Cytokinetics worth $1.42M as of Q2 2026.
  • LPL Financial bought 4,294 Cytokinetics shares in Q2 2026, an estimated $308K.
  • Cytokinetics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4106 holding.
  • LPL Financial first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.